Jove
Visualize
Contact Us

Related Experiment Videos

Maximal androgen ablation: a review.

B J Miles1, J Babiarz

  • 1Department of Urology, Henry Ford Hospital.

Henry Ford Hospital Medical Journal
|January 1, 1992
PubMed
Summary

Androgen ablation is the primary treatment for advanced prostate cancer. This review examines maximum androgen suppression, including adrenal androgens, and its effectiveness based on National Cancer Institute trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Slicing through silos: Development and evaluation of a hospital-based telehealth hepatitis C virus treatment program.

The International journal on drug policy·2024
Same author

Patents and literature.

Applied biochemistry and biotechnology·2013
Same author

Testosterone replacement therapy in the setting of prostate cancer treated with radiation.

International journal of impotence research·2012
Same author

Emerging concepts in erectile preservation following radical prostatectomy: a guide for clinicians.

International journal of impotence research·2011
Same author

Neuronal cell adhesion molecule deletion induces a cognitive and behavioral phenotype reflective of impulsivity.

Genes, brain, and behavior·2007
Same author

Knowledge of and attitudes about Alzheimer disease genetics: report of a pilot survey and two focus groups.

Community genetics·2007
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Oncology
  • Endocrinology

Background:

  • Advanced prostate cancer management relies on androgen ablation.
  • Therapeutic progress has focused on achieving castrate androgen levels.
  • The role of adrenal androgens in prostate cancer has been debated, previously considered minimal.

Purpose of the Study:

  • To review studies on maximum androgen suppression (MAS).
  • To evaluate the concept of MAS involving both testicular and adrenal androgens.
  • To emphasize findings from the largest National Cancer Institute trial on MAS.

Main Methods:

  • Review of existing studies on maximum androgen suppression.
  • Analysis of trials investigating the impact of adrenal androgen suppression.
  • Focus on a large-scale trial conducted by the National Cancer Institute.

Main Results:

  • The concept of maximum androgen suppression was reintroduced in the 1980s.
  • Some studies claimed exceptional results with MAS.
  • The National Cancer Institute conducted a significant trial evaluating this approach.

Conclusions:

  • Maximum androgen suppression, targeting both testes and adrenal glands, has been explored as an advanced prostate cancer treatment.
  • Evidence from major trials, including the National Cancer Institute's, is crucial for understanding its efficacy.
  • Further research is needed to definitively establish the role and benefit of suppressing adrenal androgens in advanced prostate cancer.

Related Experiment Videos